Electrolyte Abnormalities
Perioperative electrolyte disturbances arise from fluid shifts, bowel preparation, nasogastric losses, renal impairment, and — distinctively in GU reconstruction — the metabolic consequences of bowel segments in contact with urine. Hyperchloremic metabolic acidosis, hypokalemia, and hypomagnesemia are the characteristic long-term derangements after ileal conduit, orthotopic neobladder, and augmentation cystoplasty. In the acute perioperative window, severe hyponatremia, hyperkalemia, and refeeding-associated electrolyte shifts are the life-threatening conditions the reconstructive urologist must recognize and manage.
This article covers sodium, potassium, calcium, magnesium, and phosphate disorders — focusing on the specific thresholds, treatment regimens, and urologic-relevance points.
See also: Nutrition (refeeding syndrome — detailed there), ERAS, Cardiovascular Risk.
General Principles
- Screen preoperatively for potassium, magnesium, calcium abnormalities — these carry the highest perioperative cardiac risk.[1][2]
- Correct preoperatively when possible — preoperative potassium repletion is low-cost, low-risk, and lowers perioperative MACE.[6][7]
- Monitor actively through the perioperative window, especially after bowel surgery, cystectomy with diversion, and in any case with large volume shifts.
- Isotonic saline is the intraoperative default for fluid resuscitation in most cases; balanced crystalloid (LR, Plasma-Lyte) is preferred over saline for any patient at risk of hyperchloremic acidosis — including every diversion patient.[20]
Sodium
Hyponatremia
Serum sodium <135 mEq/L — the most common electrolyte disorder in hospitalized patients. Even mild hyponatremia is associated with increased LOS and mortality.[3]
Severity:[4]
| Grade | Sodium |
|---|---|
| Mild | 130–134 mEq/L |
| Moderate | 125–129 mEq/L |
| Severe | <125 mEq/L |
Symptom severity depends on rate of fall, duration, and absolute value — a chronic Na of 120 may be asymptomatic, while an acute Na of 128 may seize.
Perioperative relevance: acute euvolemic hyponatremia is a recognized postoperative phenomenon, driven by hypotonic fluid in the setting of surgery-induced ADH release. The reconstructive-urology classic is TURP syndrome (glycine absorption during prolonged monopolar TURP) — now rare with bipolar / saline irrigation and HoLEP, but still a testable mechanism.
Emergency treatment (severe symptoms — seizures, coma, respiratory distress):[3][4]
- 3% hypertonic saline 100–150 mL bolus over 10–20 min. Repeat up to 2–3 times until symptoms improve.
- Target: raise sodium 4–6 mEq/L within 1–2 h.
- Correction limits:
- ≤10 mEq/L in the first 24 h (standard risk)
- ≤8 mEq/L in the first 24 h (high risk for ODS)
- ≤18 mEq/L over 48 h
Osmotic demyelination syndrome (ODS) risk factors:[4]
- Sodium <105 mEq/L at presentation
- Chronicity (>48 h)
- Hypokalemia
- Alcoholism
- Malnutrition
- Advanced liver disease
Chronic management — by volume status:[3][4]
- Hypovolemic: isotonic saline for volume repletion.
- Euvolemic (SIADH): fluid restriction, salt tablets, vaptans.
- Hypervolemic: treat underlying cause (HF, cirrhosis); fluid restriction, loop diuretic.
Hypernatremia
Less common; usually driven by dehydration (impaired thirst, no access to water) or osmotic diuresis. Address the underlying etiology and replace the free-water deficit with hypotonic fluid when sodium is severely elevated or the patient is symptomatic.[4]
Potassium
Hypokalemia
Serum potassium <3.5 mEq/L. Incidence ~20% of hospitalized patients.[5]
Classification:[5]
| Grade | Potassium |
|---|---|
| Mild | 3.0–3.5 mEq/L |
| Moderate | 2.5–2.9 mEq/L |
| Severe | <2.5 mEq/L |
Perioperative significance. Preoperative K <3.5 mEq/L is associated with increased arrhythmia and cardiac events after both cardiac and non-cardiac surgery. Both hypokalemia (<3.5) and hyperkalemia (>5.5) independently predict 30-day MACE.[6][7]
- T-wave flattening / broadening
- ST depression
- Prominent U waves
- QT prolongation
- AV block, PVCs, VT, torsades de pointes, VF
Treatment — severe / symptomatic (arrhythmia, paralysis, respiratory failure, K ≤2.5):[5]
- IV KCl 5–10 mEq over 15–30 min with cardiac monitoring
- Repeat until stable, ECG normalized, K >3 mEq/L
- Further infusion: 20–40 mEq KCl in isotonic fluid at up to 10 mEq/h peripherally, up to 20 mEq/h centrally with continuous cardiac monitoring
- Use glucose-free fluid — dextrose triggers insulin release and worsens hypokalemia
- Recheck K every 2–4 h
- Check and replete magnesium — hypokalemia is often refractory until magnesium is corrected
Mild–moderate hypokalemia:[5]
- Oral KCl preferred (lower rebound hyperkalemia risk)
- Rule of thumb: 20 mEq PO raises serum K by ~0.2 mEq/L
- KCl is the most effective salt for raising serum K (vs gluconate, citrate, bicarbonate, which are less efficient)
Target K in patients with HF or CAD: 4–5 mEq/L.[5]
Hyperkalemia
Serum potassium >5.0 mEq/L. Prevalence ~3% general population, ~18% in CKD.[5]
Classification:[8]
| Grade | Potassium |
|---|---|
| Mild | 5.5–6.4 mmol/L |
| Moderate | 6.5–8.0 mmol/L |
| Severe | >8.0 mmol/L |
ECG progression (note the low sensitivity and specificity of ECG changes — absence does not reassure):[8][9]
- 5.5–6.5: peaked T waves
- 6.5–7.5: PR prolongation, flattened P
- 7.0–8.0: QRS widening
- >10: sine wave → VF → asystole
Emergent bundle (symptoms, ECG changes, or K ≥6.5):[5][10]
| Agent | Mechanism | Dose | Effect |
|---|---|---|---|
| IV calcium gluconate | Cardiac membrane stabilization | 1–2 g over 2–5 min | Immediate cardioprotection; no K change |
| Regular insulin + dextrose | Intracellular K shift | 10 U IV + 25–50 g glucose | ↓ K 0.6–1.2 mEq/L at 1 h |
| Nebulized albuterol | Intracellular K shift | 10–20 mg neb | ↓ K ~0.6 mEq/L at 30 min |
| Sodium bicarbonate | Shift (only if acidotic) | 150 mEq in 1 L D5W over 2–4 h | Variable |
| Loop diuretic | K excretion | Per urine output | Variable |
| Sodium zirconium cyclosilicate (Lokelma) | GI K binder | 10 g PO TID × 48 h | ↓ K ~0.67 mEq/L at 48 h |
| Patiromer (Veltassa) | GI K binder | 8.4 g PO daily | ↓ K ~0.70 mEq/L at 4 weeks |
| Dialysis | K removal | — | Fastest for refractory / severe |
The classic sequence: calcium first (within minutes) → insulin + beta-agonist + bicarb (shifters) → loop + binder or dialysis (removers).
Chronic management: dietary counseling, review of ACE inhibitor / ARB / K-sparing diuretic / NSAID use, long-term binder if needed.
Calcium
Hypocalcemia
Most commonly post-thyroidectomy / parathyroidectomy in the surgical setting — not a typical urologic complication, but relevant in combined endocrine cases and in patients on bisphosphonates or with severe vitamin D deficiency.[11][12]
- Oral calcium 1–3 g elemental daily (calcium carbonate or citrate)
- Active vitamin D (calcitriol 0.5 μg BID)
- Optimize 25-OH vit D and serum magnesium
Severe symptomatic (Ca <7.5 mg/dL, tetany, laryngospasm, seizure, QTc prolongation):[12]
- 12-lead ECG, measure QTc
- IV calcium gluconate 1–2 g (90–180 mg elemental) in 50 mL D5W over 20 min — peripheral OK
- Calcium chloride — 270 mg elemental/10 mL; 3× the calcium of gluconate but requires central line (severe phlebitis if extravasated peripherally)
- Continuous infusion for refractory — 0.5–1.5 mg/kg/h elemental calcium, titrate
- Continuous ECG monitoring
- Transition to oral + calcitriol as soon as feasible
Adjunct: thiazide diuretic (hydrochlorothiazide 12.5–50 mg/day) enhances renal calcium reabsorption in refractory hypocalcemia.[12]
Hypercalcemia
Hypercalcemia of malignancy is the most common cause in hospitalized patients — a real consideration in advanced prostate cancer with osseous metastases, RCC with paraneoplastic PTHrP, and squamous-cell pelvic malignancies.[13]
| Agent | Mechanism | Dose | Onset / Effect |
|---|---|---|---|
| Isotonic saline | Volume / urinary Ca excretion | 1–2 L bolus, 200–500 mL/h | Immediate; ↓ Ca 1–1.5 mg/dL in 24 h |
| Loop diuretic (after volume) | ↓ renal Ca reabsorption | Furosemide 40–60 mg/day | Minutes; ↓ Ca 0.5–1.0 mg/dL |
| Calcitonin | ↓ bone resorption | 4–8 U/kg IM/SC q6–12 h | 4–6 h; ↓ Ca 1–2; tachyphylaxis at 48–72 h |
| Pamidronate | Bisphosphonate | 60–90 mg IV over 2–24 h | 48–72 h; normalizes 60–70%, lasts 2–4 weeks |
| Zoledronic acid | Bisphosphonate | 4 mg IV over 15 min | 48–72 h; more potent than pamidronate |
| Denosumab | RANKL inhibitor | 120 mg SC | Bisphosphonate-refractory or renal failure |
Magnesium
Hypomagnesemia
Affects up to ~60% of ICU patients and is an independent risk factor for prolonged ICU stay.[14] It is systematically under-recognized.
Key clinical rule: hypomagnesemia is usually accompanied by hypocalcemia, hypokalemia, and metabolic alkalosis, and refractory hypokalemia only responds to potassium repletion after magnesium has been normalized.[14]
Causes — several are commonly encountered in the urologic patient:[14][15]
- PPIs — 20% of long-term users
- Loop and thiazide diuretics
- Calcineurin inhibitors (transplant patients)
- Cisplatin, EGFR inhibitors (advanced GU cancers)
- Aminoglycosides
- Chronic alcohol use
- GI losses (including long-term ileal-conduit output)
Symptoms: often nonspecific — lethargy, cramps, weakness; severe cases — tetany, seizures, arrhythmia (including torsades), hemodynamic instability.
Mild:
- Oral magnesium — organic salts (citrate, gluconate, aspartate, glycinate, lactate) absorb better than inorganic salts (oxide, chloride, carbonate)
- Principal side effect: diarrhea
Severe / refractory / symptomatic:
- IV magnesium sulfate 1–2 g over 15–60 min, then infusion
- For life-threatening torsades: 2 g IV over 5–10 min
- Short-bowel syndrome or ileal-conduit patients often need parenteral therapy chronically
Adjunctive strategies:[14]
- Amiloride or triamterene (K-sparing diuretics) — increase serum Mg in patients with normal renal function
- SGLT2 inhibitors — raise serum Mg, especially in diabetics
- Oral inulin for PPI-induced hypomagnesemia
Hypermagnesemia
Almost always iatrogenic — Mg-containing laxatives/antacids in a patient with impaired renal function, or obstetric Mg-sulfate therapy. Stop Mg intake; for severe cases, IV calcium for cardiac protection and dialysis for removal.[16]
Phosphate
Hypophosphatemia
A common and underrecognized disorder that affects the skeleton, hematopoietic system, striated and cardiac muscle, respiratory system, and CNS.[17][18]
Classification:[19]
| Grade | Phosphate |
|---|---|
| Mild | 2.0–2.5 mg/dL |
| Moderate | 1.0–1.9 mg/dL |
| Severe | <1.0 mg/dL |
Acute symptomatic (<1.0 mg/dL or respiratory failure, seizure, arrhythmia):
- IV sodium phosphate or potassium phosphate — dose per product-specific protocol (commonly 0.08–0.16 mmol/kg over 6 h; severe up to 0.5 mmol/kg)
- Monitor for hypocalcemia (phosphate binds calcium) and hyperphosphatemia
- Monitor K if using K-phos, especially in renal impairment
Mild–moderate / chronic:
- Oral phosphate salts (sodium or potassium phosphate, e.g., Neutra-Phos, K-Phos)
- 3–4 divided doses per day because of rapid absorption and excretion
- Active vitamin D may aid repletion in vitamin-D–deficient patients
- Side effects: diarrhea, abdominal cramping, secondary hyperparathyroidism with chronic use, nephrocalcinosis
Refeeding Syndrome
Refeeding syndrome deserves its own treatment — see Nutrition for full coverage (pathophysiology, NICE risk factors, thiamine 200–300 mg, phosphate/K/Mg repletion, 10–20 kcal/kg/day initiation advancing over 5–10 days).
The headline: in any malnourished patient, give thiamine first, replete electrolytes before feeding, start feeds low, advance slow, and check labs every 12 h for the first 3 days.
ECG Changes — Summary
| Electrolyte | Abnormality | ECG changes |
|---|---|---|
| Potassium | Hypokalemia | T flattening/broadening, ST depression, prominent U, QT prolongation |
| Potassium | Hyperkalemia | Peaked T → PR prolongation → QRS widening → sine wave → VF/asystole |
| Calcium | Hypocalcemia | QTc prolongation, risk of torsades |
| Calcium | Hypercalcemia | Shortened QT |
| Magnesium | Hypomagnesemia | Similar to hypokalemia; prolonged QT, torsades |
| Magnesium | Hypermagnesemia | Bradycardia, AV block, asystole (severe) |
GU-Specific Considerations
Bowel-in-the-Urinary-Tract Metabolic Syndrome
The reconstructive-urology signature metabolic problem. Any time a segment of bowel is in contact with urine — ileal conduit, orthotopic neobladder, continent cutaneous reservoir, augmentation cystoplasty — absorption and secretion characteristic of the bowel segment remodel the urine-blood interface.
Ileal conduit and neobladder (ileum):
- Hyperchloremic metabolic acidosis — ileum reabsorbs ammonium chloride from urine → net acid load.
- Hypokalemia — ileal mucosa can secrete potassium.
- Hypomagnesemia — chronic.
- B12 deficiency — over 5–10 years, if >15–20 cm of terminal ileum is used. Monitor annually and supplement.
- Bile salt malabsorption — diarrhea if excessive terminal ileum lost.
Jejunal conduit (now largely historical):
- Hyponatremic, hypochloremic, hyperkalemic metabolic acidosis — jejunum secretes Na and Cl and absorbs K. The opposite pattern to ileal conduit.
Colon conduit / reservoir (sigmoid, Indiana, Mainz):
- Hyperchloremic metabolic acidosis — similar mechanism to ileal.
- Hypokalemia — colon secretes K even more actively than ileum.
Management:
- Oral sodium bicarbonate (or potassium citrate if hypokalemic) to a serum bicarbonate target of ~22 mEq/L.
- Minimize urinary dwell time in the conduit — regular stoma appliance care, pouch catheterization schedule.
- Long-term B12, folate, calcium, magnesium, and vitamin D monitoring.
Perioperative Hypokalemia in the Cystectomy Patient
Multifactorial — GI losses from bowel prep, diuresis, insulin (if diabetic on sliding scale), alkalosis from NG suction. Replace aggressively preoperatively (target K 4.0 mEq/L) and monitor daily postoperatively until feeding is established.
TURP / HoLEP Dilutional Hyponatremia
With modern bipolar TURP in saline and HoLEP (saline irrigation), the classic glycine-absorption "TURP syndrome" is rare. Monitor Na and volume status intraoperatively in any monopolar case or long bipolar case with high irrigation volumes.
Radiation-Induced Nephrocalcinosis / Nephrolithiasis
Chronic abnormal urinary calcium, phosphate, citrate, and oxalate dynamics after pelvic radiation can drive stone formation. Long-term metabolic stone workup and urinary citrate supplementation may be required.
Perioperative Targets
- Sodium: 135–145 mEq/L; correct severe hyponatremia before elective surgery.
- Potassium: 3.5–5.0 mEq/L (optimal 4.0–5.0 in cardiac / CAD / HF patients).[6][7]
- Calcium: ionized Ca 1.0–1.3 mmol/L (corrected total Ca 8.5–10.5 mg/dL); correct preoperatively.
- Magnesium: 1.8–2.5 mg/dL (0.7–1.0 mmol/L); correct before K repletion in refractory hypokalemia.
- Phosphate: 2.5–4.5 mg/dL; correct symptomatic or severe (<1.0) preoperatively.
References
1. Daniels AH, Criddle SL, McDonald CL. "Electrolyte Disturbances and Repletion in Orthopaedic and Spine Surgery Patients." J Am Acad Orthop Surg. 2025;33(1):9–13. doi:10.5435/JAAOS-D-24-00402
2. Chaer R, Ochoa Chaar CI, Yuo T, et al. Society for Vascular Surgery's Multidisciplinary Management Guide on the Perioperative Care of Patients with Vascular Disease. SVS; 2023.
3. Adrogué HJ, Tucker BM, Madias NE. "Diagnosis and Management of Hyponatremia: A Review." JAMA. 2022;328(3):280–291. doi:10.1001/jama.2022.11176
4. Miller NE, Rushlow D, Stacey SK. "Diagnosis and Management of Sodium Disorders: Hyponatremia and Hypernatremia." Am Fam Physician. 2023;108(5):476–486.
5. Kim MJ, Valerio C, Knobloch GK. "Potassium Disorders: Hypokalemia and Hyperkalemia." Am Fam Physician. 2023;107(1):59–70.
6. Wahr JA, Parks R, Boisvert D, et al. "Preoperative Serum Potassium Levels and Perioperative Outcomes in Cardiac Surgery Patients." JAMA. 1999;281(23):2203–10. doi:10.1001/jama.281.23.2203
7. Arora P, Pourafkari L, Visnjevac O, et al. "Preoperative Serum Potassium Predicts the Clinical Outcome After Non-Cardiac Surgery." Clin Chem Lab Med. 2017;55(1):145–153. doi:10.1515/cclm-2016-0038
8. Sandau KE, Funk M, Auerbach A, et al. "Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings — AHA Scientific Statement." Circulation. 2017;136(19):e273–e344. doi:10.1161/CIR.0000000000000527
9. Ferreira JP, Butler J, Rossignol P, et al. "Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review." J Am Coll Cardiol. 2020;75(22):2836–2850. doi:10.1016/j.jacc.2020.04.021
10. Batterink J, Cessford TA, Taylor RA. "Pharmacological Interventions for the Acute Management of Hyperkalaemia in Adults." Cochrane Database Syst Rev. 2015;10:CD010344. doi:10.1002/14651858.CD010344.pub2
11. Edafe O, Mech CE, Balasubramanian SP. "Calcium, Vitamin D or Recombinant Parathyroid Hormone for Managing Post-Thyroidectomy Hypoparathyroidism." Cochrane Database Syst Rev. 2019;5:CD012845. doi:10.1002/14651858.CD012845.pub2
12. Orloff LA, Wiseman SM, Bernet VJ, et al. "American Thyroid Association Statement on Postoperative Hypoparathyroidism." Thyroid. 2018;28(7):830–841. doi:10.1089/thy.2017.0309
13. El-Hajj Fuleihan G, Clines GA, Hu MI, et al. "Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2023;108(3):507–528. doi:10.1210/clinem/dgac621
14. Touyz RM, de Baaij JHF, Hoenderop JGJ. "Magnesium Disorders." N Engl J Med. 2024;390(21):1998–2009. doi:10.1056/NEJMra1510603
15. Rosner MH, Ha N, Palmer BF, Perazella MA. "Acquired Disorders of Hypomagnesemia." Mayo Clin Proc. 2023;98(4):581–596. doi:10.1016/j.mayocp.2022.12.002
16. Kröse JL, de Baaij JHF. "Magnesium Biology." Nephrol Dial Transplant. 2024;39(12):1965–1975. doi:10.1093/ndt/gfae134
17. Florenzano P, Cipriani C, Roszko KL, et al. "Approach to Patients With Hypophosphataemia." Lancet Diabetes Endocrinol. 2020;8(2):163–174. doi:10.1016/S2213-8587(19)30426-7
18. Netzer S, Büchel L, Büchi AE, Aubert CE. "Indications for the Evaluation and Supplementation of Hypophosphatemia: An Umbrella Systematic Review of Reviews and Guidelines." BMC Med. 2025;23(1):591. doi:10.1186/s12916-025-04415-1
19. Felsenfeld AJ, Levine BS. "Approach to Treatment of Hypophosphatemia." Am J Kidney Dis. 2012;60(4):655–61. doi:10.1053/j.ajkd.2012.03.024
20. Lorente JV, Hervías Sanz M, Ripollés-Melchor J, Hahn RG. "Perioperative Fluid Therapy in Adults and Children: A Narrative Review." Front Med. 2025;12:1607670. doi:10.3389/fmed.2025.1607670